Deutsch
 
Benutzerhandbuch Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Hochschulschrift

Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen Vergleich: Eine institutionentheoretische Analyse

MPG-Autoren
/persons/resource/persons41234

Lange,  Knut Stefan Garrit
Wissenschaft, Technik und Innovationssysteme, MPI for the Study of Societies, Max Planck Society;

Externe Ressourcen

http://irs.ub.rug.nl/ppn/292008961
(beliebiger Volltext)

Volltexte (frei zugänglich)

mpifg_diss06_Lange.pdf
(beliebiger Volltext), 2MB

Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Lange, K. S. G. (2006). Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen Vergleich: Eine institutionentheoretische Analyse. PhD Thesis, Rijksuniversiteit Groningen, Groningen, Niederlande.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0012-4ACF-2
Zusammenfassung
Summary 1. Introduction In the mid-1990s, legal changes and policy initiatives in Germany led to the rapid emergence of a biotechnology industry. Initially, German biotech companies focused on the market segment of platform technologies, characterized by incremental innovations. In recent years however, many companies have shifted their strategic focus on the market segment of therapeutics, characterized by radical innovations. Since an active involvement in such a segment is untypical for German companies the central research question of this thesis was, if the German institutional framework allowed biotech companies to be internationally competitive in a radical-innovative market segment. The findings are particularly relevant for the literatures on “Varieties of Capitalism”, “National Innovation Systems” and for the sociology of technology. The British and the US biotech industry served as a comparison for the validation of the German case study.